Company Overview and News
CAIRO (Sept 15): Egypt has signed a deep-water oil and gas exploration deal with Royal Dutch Shell and Malaysia's Petronas worth around US$1 billion for 8 wells in the country's West Nile Delta, the petroleum ministry said on Saturday.
RDS.B DOV.WI RDS.A RYDBF DOV RDSB RDSA RYDAF
Shares of Dover Corporation (DOV - Free Report) reached a new high after it announced a rightsizing plan to improve the company’s operating margin performance. The move will also enhance its operations, thereby facilitating sustainable growth and investments. Dover’s shares crafted a 52-week high of $88.60 during intra-day trading, finally closing lower at $86.22, on Sep 11. During the June-end quarter, Dover’s selling, general and administrative (SG&A) costs flared up 1.
DOV.WI B CFX DOV FLS
2018-09-08 seekingalpha - 1
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
KMT DISCB DISCA LBTY TWX LCII PGR DISCK IMAX CNK WMT IT LBTYK LILAB VIAB DOV BOX NWY TSM OCFC DISC VFC UPS NWS TTWO NWSA LAMR IEP OXM JNJ WIN LILAK VZ MBUU TLRD ALV.WI FARM HD KKR AIHS RCUS SSNLF TM ZS BWB NLSN CRTO WGO KLAC ATVI TEN JMBA SUOPY KR NWS AAPL AMTD BEN LYV CCI PSDO ATUS MCD CWH VIA GJV EA EVHC CMCSA LBTYB THO LBTYA RHP HMC CASY TGT S LPL T PLAY HPQ ATEYY LILA
2018-09-03 seekingalpha - 2
This is a follow-up to my August 20, 2018 article, which included a portfolio review, but not sector information. (Note to non-PRO subscribers: I've avoided writing single ticker articles to prevent them from being paywalled, but SA made the dual-ticker August 20 article an Editor's Pick and paywalled it. C'est la vie.)
SOJA VT TXN RDSB RDSA IMO AAPL DOV GSK RYDAF INTC ORCL LEG SO DUKH IMO RDS.B GEC GE RDS.A DUK GSK MFC BLK TGT 0945 CVX RYDBF GNE MFC MSFT OXY
Dover Corporation (DOV - Free Report) has been witnessing encouraging improvement over the past few quarters, majorly driven by strong bookings, cost-reduction initiatives and restructuring programs. The company will benefit from the spin-off of Apergy. However, challenges in the Fluids segment and foreign-exchange volatility remain headwinds. This Zacks Rank #3 (Hold) company has an estimated long-term earnings growth rate of 12%.
DOV.WI GWW SCVL ATKR IRBT DOV PAYC
One popular form of dividend investing involves a group of stocks called dividend aristocrats. Standards of what makes up a dividend aristocrat vary. However, most analysts define it by three criteria. One, they must belong to the S&P 500 index. Two, they meet specific size and liquidity metrics. Three, and most importantly, they must have increased their dividend for 25 or more consecutive years.
IBM PG AMZN DOV.WI T JNJ TSLA CSCO DOV
2018-08-12 seekingalpha - 7
Dan Loeb's 13F portfolio value increased from $13.32B to $14.35B this quarter. The number of positions decreased from 40 to 38.
ATHTF STZ.B TWX CRM DOW DOV MELI PBF TPRE WP KDMN STZ UTX BKI TWC PVH DVMT FPAC.U GOOGL MSFT APY MHK TPNTF GRBK FB DOV.WI LEN NXPI PYPL NFLX BAX GOOG LEN.B MPC PAGS ADBE SPGI EGN MON ICE SHY CWH EA WYNN ANTM DWDP BID BLK V DHR ANTX
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to DOV / Dover Corp. on message board site Silicon Investor.
as of ET